Heron Total Liab vs Cash And Short Term Investments Analysis

HRTX Stock  USD 1.06  0.06  5.36%   
Heron Therapeuti financial indicator trend analysis is much more than just examining Heron Therapeuti latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Heron Therapeuti is a good investment. Please check the relationship between Heron Therapeuti Total Liab and its Cash And Short Term Investments accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Heron Therapeuti. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy Heron Stock please use our How to Invest in Heron Therapeuti guide.

Total Liab vs Cash And Short Term Investments

Total Liab vs Cash And Short Term Investments Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Heron Therapeuti Total Liab account and Cash And Short Term Investments. At this time, the significance of the direction appears to have almost no relationship.
The correlation between Heron Therapeuti's Total Liab and Cash And Short Term Investments is 0.13. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Cash And Short Term Investments in the same time period over historical financial statements of Heron Therapeuti, assuming nothing else is changed. The correlation between historical values of Heron Therapeuti's Total Liab and Cash And Short Term Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of Heron Therapeuti are associated (or correlated) with its Cash And Short Term Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash And Short Term Investments has no effect on the direction of Total Liab i.e., Heron Therapeuti's Total Liab and Cash And Short Term Investments go up and down completely randomly.

Correlation Coefficient

0.13
Relationship DirectionPositive 
Relationship StrengthInsignificant

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Heron Therapeuti balance sheet. This account contains Heron Therapeuti investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Heron Therapeuti fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.
Most indicators from Heron Therapeuti's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Heron Therapeuti current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Heron Therapeuti. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy Heron Stock please use our How to Invest in Heron Therapeuti guide.At this time, Heron Therapeuti's Selling General Administrative is fairly stable compared to the past year. Discontinued Operations is likely to rise to about 1.3 M in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 28.3 M in 2024.
 2021 2022 2023 2024 (projected)
Total Operating Expenses258.2M227.5M172.6M181.2M
Cost Of Revenue46.0M54.9M65.1M68.4M

Heron Therapeuti fundamental ratios Correlations

0.230.890.860.780.760.07-0.650.280.660.230.910.780.640.00.770.50.661.00.410.710.710.35-0.09-0.06-0.7
0.230.560.48-0.420.620.91-0.86-0.230.770.87-0.150.640.850.930.770.950.770.150.050.770.19-0.090.00.22-0.52
0.890.560.960.440.90.38-0.890.170.840.460.650.910.880.310.950.790.870.850.480.890.730.25-0.090.03-0.81
0.860.480.960.460.780.25-0.810.320.720.360.660.90.810.180.880.730.750.840.680.80.650.46-0.12-0.03-0.8
0.78-0.420.440.460.31-0.51-0.040.390.13-0.320.950.290.04-0.570.21-0.150.110.830.280.160.520.34-0.07-0.19-0.31
0.760.620.90.780.310.46-0.880.110.970.60.490.750.840.440.910.780.940.70.240.90.84-0.14-0.020.09-0.75
0.070.910.380.25-0.510.46-0.7-0.610.60.77-0.290.510.70.890.60.810.630.0-0.260.650.0-0.20.050.27-0.37
-0.65-0.86-0.89-0.81-0.04-0.88-0.70.0-0.92-0.74-0.3-0.88-0.98-0.7-0.98-0.97-0.94-0.58-0.29-0.95-0.56-0.060.03-0.150.72
0.28-0.230.170.320.390.11-0.610.00.04-0.140.390.03-0.02-0.320.06-0.09-0.010.30.71-0.060.370.3-0.12-0.21-0.11
0.660.770.840.720.130.970.6-0.920.040.790.340.740.860.610.910.870.920.590.180.930.74-0.150.010.13-0.73
0.230.870.460.36-0.320.60.77-0.74-0.140.79-0.10.490.670.840.660.810.620.15-0.030.750.28-0.140.060.18-0.47
0.91-0.150.650.660.950.49-0.29-0.30.390.34-0.10.50.3-0.350.460.130.330.940.380.370.580.42-0.11-0.17-0.46
0.780.640.910.90.290.750.51-0.880.030.740.490.50.90.410.910.830.810.750.440.890.460.39-0.040.13-0.83
0.640.850.880.810.040.840.7-0.98-0.020.860.670.30.90.690.980.960.940.590.280.910.490.08-0.070.15-0.7
0.00.930.310.18-0.570.440.89-0.7-0.320.610.84-0.350.410.690.580.790.61-0.08-0.210.590.01-0.290.110.33-0.22
0.770.770.950.880.210.910.6-0.980.060.910.660.460.910.980.580.920.940.710.330.950.630.11-0.050.12-0.75
0.50.950.790.73-0.150.780.81-0.97-0.090.870.810.130.830.960.790.920.880.430.250.90.40.08-0.040.17-0.69
0.660.770.870.750.110.940.63-0.94-0.010.920.620.330.810.940.610.940.880.590.190.890.65-0.16-0.010.18-0.73
1.00.150.850.840.830.70.0-0.580.30.590.150.940.750.59-0.080.710.430.590.420.640.670.4-0.09-0.08-0.67
0.410.050.480.680.280.24-0.26-0.290.710.18-0.030.380.440.28-0.210.330.250.190.420.210.310.62-0.13-0.14-0.48
0.710.770.890.80.160.90.65-0.95-0.060.930.750.370.890.910.590.950.90.890.640.210.640.080.010.15-0.77
0.710.190.730.650.520.840.0-0.560.370.740.280.580.460.490.010.630.40.650.670.310.64-0.11-0.01-0.04-0.54
0.35-0.090.250.460.34-0.14-0.2-0.060.3-0.15-0.140.420.390.08-0.290.110.08-0.160.40.620.08-0.11-0.17-0.2-0.25
-0.090.0-0.09-0.12-0.07-0.020.050.03-0.120.010.06-0.11-0.04-0.070.11-0.05-0.04-0.01-0.09-0.130.01-0.01-0.170.950.16
-0.060.220.03-0.03-0.190.090.27-0.15-0.210.130.18-0.170.130.150.330.120.170.18-0.08-0.140.15-0.04-0.20.950.05
-0.7-0.52-0.81-0.8-0.31-0.75-0.370.72-0.11-0.73-0.47-0.46-0.83-0.7-0.22-0.75-0.69-0.73-0.67-0.48-0.77-0.54-0.250.160.05
Click cells to compare fundamentals

Heron Therapeuti Account Relationship Matchups

Heron Therapeuti fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets512.8M353.6M305.7M251.0M222.5M233.6M
Short Long Term Debt Total19.8M24.6M159.5M157.5M179.6M188.6M
Other Current Liab86.4M88.9M62.4M73.7M70.3M73.8M
Total Current Liabilities96.7M102.5M71.1M82.4M79.7M83.7M
Total Stockholder Equity403.8M236.5M77.6M13.6M(34.0M)(32.3M)
Property Plant And Equipment Net33.4M39.0M33.6M29.8M25.6M26.9M
Net Debt(52.1M)(80.5M)69.0M142.1M151.0M158.5M
Retained Earnings(1.2B)(1.4B)(1.6B)(1.8B)(1.9B)(1.8B)
Cash71.9M105.1M90.5M15.4M28.7M27.8M
Non Current Assets Total33.7M39.4M51.3M45.5M33.7M35.4M
Cash And Short Term Investments391.0M208.5M157.6M84.9M80.4M60.9M
Net Receivables39.9M41.9M35.5M52.0M60.1M63.1M
Common Stock Shares Outstanding81.8M90.8M98.5M108.9M138.1M145.0M
Liabilities And Stockholders Equity512.8M353.6M305.7M251.0M222.5M233.6M
Non Current Liabilities Total12.2M14.6M157.1M155.0M176.8M185.6M
Other Stockholder Equity1.6B1.6B1.7B1.8B1.9B2.0B
Total Liab108.9M117.1M228.1M237.4M256.5M269.3M
Property Plant And Equipment Gross33.4M39.0M33.6M29.8M42.6M44.8M
Total Current Assets479.1M314.2M254.4M205.4M188.8M198.2M
Accumulated Other Comprehensive Income85K257K(6K)(19K)13K13.7K
Short Term Debt7.6M13.0M4.8M5.4M6.2M4.0M
Inventory25.0M41.9M48.4M54.6M42.1M44.2M
Other Current Assets23.2M43.9M25.9M14.0M6.1M5.5M
Accounts Payable2.8M525K3.8M3.2M3.2M3.2M
Common Stock Total Equity782K903K913K1.0M1.2M658.0K
Common Stock903K913K1.0M1.2M1.5M1.6M
Other Assets346K16.6M17.7M15.7M18.1M19.0M
Short Term Investments319.1M103.4M67.0M69.5M51.7M55.8M
Property Plant Equipment19.6M22.7M33.6M29.8M34.3M36.0M
Net Tangible Assets403.8M236.5M77.6M13.6M15.6M14.8M
Retained Earnings Total Equity(960.7M)(1.2B)(1.4B)(1.6B)(1.5B)(1.4B)
Capital Surpluse1.3B1.6B1.6B1.7B1.9B2.0B
Short Long Term Debt28.7M4.6M5.6M7.1M8.1M8.3M
Net Invested Capital409.5M243.5M226.7M162.9M139.8M196.2M
Net Working Capital382.4M211.7M183.4M123.1M109.1M170.3M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Heron Stock Analysis

When running Heron Therapeuti's price analysis, check to measure Heron Therapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Heron Therapeuti is operating at the current time. Most of Heron Therapeuti's value examination focuses on studying past and present price action to predict the probability of Heron Therapeuti's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Heron Therapeuti's price. Additionally, you may evaluate how the addition of Heron Therapeuti to your portfolios can decrease your overall portfolio volatility.